CELG

Celgene Corporation Press Releases

$116.09
*  
0.11
0.09%
Get CELG Alerts
*Delayed - data as of May 22, 2015  -  Find a broker to begin trading CELG now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By



Analysis of Phase II Data for Celgene’s Investigational Oral GED-0301 in Patients with Active Crohn’s Disease Presented at Digestive Disease Week
5/19/2015 8:15:00 AM - Business Wire
▼-0.57 % Price Change since this news event. The Volume Ratio is 0.88.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Beta-Thalassemia
5/18/2015 7:30:00 AM - Business Wire
▲0.77 % Price Change since this news event. The Volume Ratio is 1.01.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Celgene Announces Presentations of Investigational Studies in Solid Tumor and Blood Cancers at ASCO 2015
5/13/2015 5:18:00 PM - Business Wire
▲2.77 % Price Change since this news event. The Volume Ratio is 0.7.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day






Celgene to Acquire Quanticel Pharmaceuticals
4/27/2015 7:30:00 AM - Business Wire